CDK4 and breast cancer: It will be important in the future to measure replication stress directly in breast cancer patients treated with CDK4/6 inhibitors, and to compare this in patients who are dosed continuously, as with abemaciclib, or in repeated on/off cycles, as with palbociclib/ribociclib (Pernas et al, 2018).